WO2008063569A1 - Co-mixed human fat and gel suspension implant material - Google Patents

Co-mixed human fat and gel suspension implant material Download PDF

Info

Publication number
WO2008063569A1
WO2008063569A1 PCT/US2007/024094 US2007024094W WO2008063569A1 WO 2008063569 A1 WO2008063569 A1 WO 2008063569A1 US 2007024094 W US2007024094 W US 2007024094W WO 2008063569 A1 WO2008063569 A1 WO 2008063569A1
Authority
WO
WIPO (PCT)
Prior art keywords
fat
gel suspension
gel
fill material
human
Prior art date
Application number
PCT/US2007/024094
Other languages
French (fr)
Inventor
Hugo A. Cobar
Original Assignee
Coapt Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coapt Systems, Inc. filed Critical Coapt Systems, Inc.
Publication of WO2008063569A1 publication Critical patent/WO2008063569A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0059—Cosmetic or alloplastic implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/12—Mammary prostheses and implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
    • A61M2005/31516—Piston or piston-rod constructions, e.g. connection of piston with piston-rod reducing dead-space in the syringe barrel after delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly

Definitions

  • the present invention relates to implant materials, and in particular a unique fill material that combines human fat and a gel suspension.
  • Injectable fill materials are well known, and are used to treat voids in the human body, such as facial wrinkles.
  • One known fill material is autologous fat (fat harvested from the same patient that receives it). This autologous fat is known to be used in reconstructive, cosmetic, and correctional surgery. It is advantageous for the patient because it will not cause a negative reaction. It also has the advantage that it can become a soft permanent correction if it vascularizes and regenerates.
  • processing the harvested fat while retaining cell viability can be difficult and result in producing insufficient amounts of viable fat suitable for re-injection.
  • transplanting larger volumes of fat can lead to necrosis of some of the transplanted tissue, which over time, has been shown to cause a 40-60% reduction in the graft volume. Greater success can be achieved in transplanting smaller volumes of fat where diffusion can support cell survival.
  • ASCs adipose derived stem cells
  • Another known class of fill materials is synthetic gel fillers.
  • the advantages of these types of gel fillers are ease of use and no need to harvest fat from the patient.
  • such gel fillers are biodegradable, so that over time the void into which they are injected will reappear.
  • additives such as CaHA, PMMA or PLA beads have been added to the fills. These materials are not radiolucent and thus would interfere with medical imaging, and have had a history of other problems.
  • the fill material is for injection into a human patient, and includes human fat harvested from a patient, and a gel suspension co-mixed with the fat.
  • Fig. 1 is a cross sectional view of a double barrel mixing syringe for mixing and injecting the human fat and gel suspension material.
  • the present invention is a unique fill material suitable for all tissue fill applications including large volume restoration or augmentation such as the buttock and breast.
  • the unique fill material includes autologous human fat filler co-mixed with a gel suspension.
  • the purpose of co-mixing the autologous human fat filler with a gel suspension is to provide a larger volume filler that allows angiogenesis and vasculogenesis of the adipose tissue while maintaining its volume.
  • the autologous human fat co-mixed with a gel suspension is a biocompatible, radiolucent, longer lasting, multipotent filler.
  • the autologous human fat is obtained by manual or vacuum assisted aspiration of fat from a patient. To obtain the best result, the fat aspirant should be processed to eliminate a majority of blood and oil.
  • the "gel" suspension is any appropriate material (implantable, biocompatible, biodegradable and sterile) that has a viscosity greater than that of water.
  • the gel suspension would also, but not necessarily, be substantially radiolucent, have long lasting volume enhancing properties, preserve volume (resulting mixed volume is no less than premixed volumes added together), or enhance volume (resulting mixed volume exceeds premixed volumes added together).
  • the gel suspension should be radiolucent and not contain any particles that might become points of calcification.
  • the gel suspension could contain materials for drawing water into the area for bulking, such as hyaluronic acid, or for adding bulk with or with out particles using a carrier to aide in injection.
  • the gel suspension can be organic or inorganic.
  • synthetic materials suitable for the gel suspension which have been reviewed and approved by the FDA.
  • the FDA classifies these materials as implant, dermal, for aesthetic use. Any of these materials would fall under the gel suspension definition as used herein, given their viscosities are greater than that of water.
  • These materials are generally biocompatible, sterile, and implantable in the dermis for the correction of moderate to severe facial wrinkles and folds and/or other soft tissue contour deficiencies.
  • HA hyaluronic acid
  • streptococcal bacteria a synthetic material suitable as the gel suspension
  • HA is an acid that is produced naturally by the body.
  • Restylane® Injectable Gel distributed by A-Med, Inc.
  • poly-L-lactic acid a biocompatible, biodegradable, synthetic polymer from the apha-hydroxy-acid family.
  • This poly-L-lactic acid comes in the form of a sterile lyophilized cake which is then reconstituted prior to use by the addition of sterile water for injection, USP (SWFI) to form a sterile non-pyrogenic gel suspension.
  • SWFI sterile water for injection
  • poly-L-lactic acid based gels is SCULPTRATM, manufactured by Aventis Pharmaceuticals Inc.
  • a suitable organic gel suspension is human-based collagen.
  • human-based collagen materials are CosmoDermTM 1 and 2, and CosmoPlastTM, manufactured by Allergan. These materials are composed of highly purified human-based collagen that is dispersed in phosphate-buffered physiological saline containing 0.3% lidocaine.
  • gel suspension materials suitable for soft tissue augmentation include, but are not limited to, bovine based collagen fillers (Zyderm® and Zyplast®), fibrin glue, alginate and RGD and YGSIR-modified alginate gels.
  • RGD and YGRID are cell-binding sequences of laminin and fibronectic, respectively. These binding sequences are used to help the cells bind to an engineered construct.
  • non- synthetic gel materials that are implantable, biocompatible, biodegradable, sterile, and have a viscosity greater than water can also be mixed with the autologous fat filler to result in the co-mixed fill material suitable for tissue fill applications.
  • non-synthetic materials can include monomers and/or polymers from materials such as acids, proteins and carbohydrates.
  • One suitable mixing technique is the use of a double barrel mixing syringe 10, which includes a pair of chambers 12a/ 12b in fluid communication with a mixing nozzle 14 that efficiently mixes and injects the fat and gel materials from the two chambers as plungers 16a/16b are pressed downward in chambers 12a/12b, as shown in Fig 1.
  • the mixing nozzle 14 terminates in a surgical needle tip that can be inserted into the patient.
  • the use of syringe 10 is advantageous because the syringe 10 will mix the fat and gel in the desired proportions, while injecting the mixture into the target site, all in a single action.
  • the human fat and gel suspension can be mixed together in a container before being added to a syringe or other delivery device.
  • Other well known mixing techniques could be used as well, such as mixing paddles or a "add and shake" technique.
  • One advantage of using a fill material of autologous fat and gel suspension is that gel suspension acts as a biocompatible, bio-absorbable, intracellular matrix taking up volume while the adipose tissue has time to undergo angiogenesis, vasculogenesis, and the more immediate inosculation. As the gel suspension is slowly being absorbed by the body, the adipose tissue, since it is relative thinned out, will vascularize, re-grow, and fill the volume being left behind by the gel suspension as it is being absorbed; ultimately providing a full correction of the treated area.
  • This feature also provides the added benefit of using this co-mixture for larger fill procedures like breast augmentations. In larger fill procedures, it is sometimes very difficult to harvest the necessary volume of adipose tissue. Thus, using the fat and gel co-mixture helps solve this problem.
  • Another advantage of using co-mixed autologous fat and gel suspension is that it allows the autologous fat within the suspension to be thinly injected.
  • the thin cross section of the autologous fat allows each fat cell greater access to the vasculature surrounding it and therefore greater ability to vascularize and regenerate. It also allows for the fat to grow through the gel suspension creating its own 3D matrix.
  • an injection of only autologous fat would have a cross section of 100% harvested fat. The fat cells in the center of this cross section would have minimal, if any, access to the vasculature of the tissue surrounding it, thereby being susceptible to cell necrosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A fill material and method for treating human voids such as wrinkles. The fill material is a co-mixture of human fat from a patient and a gel suspension. After the fat and gel are mixed together, they are injected back into the patient from which the fat was harvested.

Description

CO-MIXED HUMAN FAT AND GEL SUSPENSION IMPLANT MATERIAL
[0001] This application claims the benefit of U.S. Provisional Application No. 60/859,877, filed November 16, 2006.
FIELD OF THE INVENTION
[0002] The present invention relates to implant materials, and in particular a unique fill material that combines human fat and a gel suspension.
BACKGROUND OF THE INVENTION [0003] Injectable fill materials are well known, and are used to treat voids in the human body, such as facial wrinkles. One known fill material is autologous fat (fat harvested from the same patient that receives it). This autologous fat is known to be used in reconstructive, cosmetic, and correctional surgery. It is advantageous for the patient because it will not cause a negative reaction. It also has the advantage that it can become a soft permanent correction if it vascularizes and regenerates. There are some drawbacks, however, of using only viable fat as a filler. The viable fat must first be harvested from the patient. Since only a fraction of the harvested fat is suitable for re-injection, it can be problematic to harvest enough fat for the re-injection procedure. Also, processing the harvested fat while retaining cell viability can be difficult and result in producing insufficient amounts of viable fat suitable for re-injection. In addition, transplanting larger volumes of fat can lead to necrosis of some of the transplanted tissue, which over time, has been shown to cause a 40-60% reduction in the graft volume. Greater success can be achieved in transplanting smaller volumes of fat where diffusion can support cell survival.
[0004] Within the stromal vascular fraction of adipose tissue there are mesenchymal preadipocytes that are now thought to be adipose derived stem cells (ASCs). These multipotent ASCs have been shown to differentiate into adult adipocytes, back to preadipocytes, and into other cell types, including cartilage and bone. Many present studies have been focused on these individual ASCs for their regenerative and multipotent properties, as well as seeding them within an engineered porous scaffold, matrix and or construct. These matrices or scaffolds have been known to be made from synthetic protein- coated polytetrafiuoroethylene, synthetic biodegradable PLGA, polyglycolic or hyaluronic acids and collagen. However, extensive additional time and effort must be spent isolating the ASCs from the stromal vascular fraction with live and potent enzymes that catalyze the hydrolysis of the connective tissue. Typical enzymes to use for this hydrolysis are Collagenase Type I & Type II, and Trypsin. In addition, even though the ASCs undergo "washing" during the isolation process, there is a risk of introducing these harmful, potent enzymes within the transplanted tissue.
[0005] Another known class of fill materials is synthetic gel fillers. The advantages of these types of gel fillers are ease of use and no need to harvest fat from the patient. However, such gel fillers are biodegradable, so that over time the void into which they are injected will reappear. To increase the duration of the fill, additives such as CaHA, PMMA or PLA beads have been added to the fills. These materials are not radiolucent and thus would interfere with medical imaging, and have had a history of other problems.
[0006] There is a need for an improved fill material that provides instant volume correction, actively promotes tissue in-growth for a near permanent fill, is radiolucent so it will not interfere with medical imaging, does not contain beads of material which could lead to calcifications, and can be supplied in large volumes to support surgeries where large volumes are required, such as breast and buttock rejuvenation procedures.
SUMMARY OF THE INVENTION
[0007] The aforementioned problems and needs are addressed by providing a fill material utilizing a mixture of both harvested human fat and a gel suspension, which can effectively be used to fill large volumes, provides better access of fat cells to surrounding tissue, and can be radiolucent to not interfere with diagnostic testing.
[0008] The fill material is for injection into a human patient, and includes human fat harvested from a patient, and a gel suspension co-mixed with the fat.
[0009] Other objects and features of the present invention will become apparent by a review of the specification, claims and appended figures.
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Fig. 1 is a cross sectional view of a double barrel mixing syringe for mixing and injecting the human fat and gel suspension material. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] The present invention is a unique fill material suitable for all tissue fill applications including large volume restoration or augmentation such as the buttock and breast. The unique fill material includes autologous human fat filler co-mixed with a gel suspension. The purpose of co-mixing the autologous human fat filler with a gel suspension is to provide a larger volume filler that allows angiogenesis and vasculogenesis of the adipose tissue while maintaining its volume. The autologous human fat co-mixed with a gel suspension is a biocompatible, radiolucent, longer lasting, multipotent filler.
[0012] The autologous human fat is obtained by manual or vacuum assisted aspiration of fat from a patient. To obtain the best result, the fat aspirant should be processed to eliminate a majority of blood and oil.
[0013] As used herein, the "gel" suspension is any appropriate material (implantable, biocompatible, biodegradable and sterile) that has a viscosity greater than that of water. Ideally, the gel suspension would also, but not necessarily, be substantially radiolucent, have long lasting volume enhancing properties, preserve volume (resulting mixed volume is no less than premixed volumes added together), or enhance volume (resulting mixed volume exceeds premixed volumes added together). For procedures such as breast augmentation, the gel suspension should be radiolucent and not contain any particles that might become points of calcification. For other applications, the gel suspension could contain materials for drawing water into the area for bulking, such as hyaluronic acid, or for adding bulk with or with out particles using a carrier to aide in injection.
[0014] The gel suspension can be organic or inorganic. There are a number of synthetic materials suitable for the gel suspension which have been reviewed and approved by the FDA. The FDA classifies these materials as implant, dermal, for aesthetic use. Any of these materials would fall under the gel suspension definition as used herein, given their viscosities are greater than that of water. These materials are generally biocompatible, sterile, and implantable in the dermis for the correction of moderate to severe facial wrinkles and folds and/or other soft tissue contour deficiencies.
[0015] One of the more popular synthetic material suitable as the gel suspension is stabilized, hyaluronic acid (HA) generated by streptococcal bacteria and formulated to a specified concentration, suspended in a physiological buffer with a specified pH level. HA is an acid that is produced naturally by the body. One specific example of a HA based gel suspension is Restylane® Injectable Gel, distributed by A-Med, Inc.
[0016] Another popular synthetic material is injectable microparticles of poly-L-lactic acid, a biocompatible, biodegradable, synthetic polymer from the apha-hydroxy-acid family. This poly-L-lactic acid comes in the form of a sterile lyophilized cake which is then reconstituted prior to use by the addition of sterile water for injection, USP (SWFI) to form a sterile non-pyrogenic gel suspension. One specific example of poly-L-lactic acid based gels is SCULPTRA™, manufactured by Aventis Pharmaceuticals Inc.
[0017] A suitable organic gel suspension is human-based collagen. Specific examples of human-based collagen materials are CosmoDerm™ 1 and 2, and CosmoPlast™, manufactured by Allergan. These materials are composed of highly purified human-based collagen that is dispersed in phosphate-buffered physiological saline containing 0.3% lidocaine.
[0018] Other gel suspension materials suitable for soft tissue augmentation include, but are not limited to, bovine based collagen fillers (Zyderm® and Zyplast®), fibrin glue, alginate and RGD and YGSIR-modified alginate gels. RGD and YGRID are cell-binding sequences of laminin and fibronectic, respectively. These binding sequences are used to help the cells bind to an engineered construct.
[0019] It should be noted that while synthetic gel suspensions are preferred, non- synthetic gel materials that are implantable, biocompatible, biodegradable, sterile, and have a viscosity greater than water can also be mixed with the autologous fat filler to result in the co-mixed fill material suitable for tissue fill applications. Examples of such non-synthetic materials can include monomers and/or polymers from materials such as acids, proteins and carbohydrates. [0020] Once the human fat and gel suspension are prepared, they are mixed together, preferably at a 1 :1 ratio. However, the ratio may change to provide the best results. One suitable mixing technique is the use of a double barrel mixing syringe 10, which includes a pair of chambers 12a/ 12b in fluid communication with a mixing nozzle 14 that efficiently mixes and injects the fat and gel materials from the two chambers as plungers 16a/16b are pressed downward in chambers 12a/12b, as shown in Fig 1. Preferably, but not necessarily, the mixing nozzle 14 terminates in a surgical needle tip that can be inserted into the patient. The use of syringe 10 is advantageous because the syringe 10 will mix the fat and gel in the desired proportions, while injecting the mixture into the target site, all in a single action. Alternately, the human fat and gel suspension can be mixed together in a container before being added to a syringe or other delivery device. Other well known mixing techniques could be used as well, such as mixing paddles or a "add and shake" technique.
[0021] One advantage of using a fill material of autologous fat and gel suspension is that gel suspension acts as a biocompatible, bio-absorbable, intracellular matrix taking up volume while the adipose tissue has time to undergo angiogenesis, vasculogenesis, and the more immediate inosculation. As the gel suspension is slowly being absorbed by the body, the adipose tissue, since it is relative thinned out, will vascularize, re-grow, and fill the volume being left behind by the gel suspension as it is being absorbed; ultimately providing a full correction of the treated area. This feature also provides the added benefit of using this co-mixture for larger fill procedures like breast augmentations. In larger fill procedures, it is sometimes very difficult to harvest the necessary volume of adipose tissue. Thus, using the fat and gel co-mixture helps solve this problem.
[0022] Another advantage of using co-mixed autologous fat and gel suspension is that it allows the autologous fat within the suspension to be thinly injected. The thin cross section of the autologous fat allows each fat cell greater access to the vasculature surrounding it and therefore greater ability to vascularize and regenerate. It also allows for the fat to grow through the gel suspension creating its own 3D matrix. In contrast, an injection of only autologous fat would have a cross section of 100% harvested fat. The fat cells in the center of this cross section would have minimal, if any, access to the vasculature of the tissue surrounding it, thereby being susceptible to cell necrosis.
[0023] Yet one more advantage of using co-mixed autologous fat and gel suspension is that many suitable gel suspensions are radiolucent. This allows the gel suspension to be invisible to x-rays, which greatly benefits future diagnostic testing such as mammograms. Further, the co-mixture of autologous fat and gel suspension is easier and more time efficient to use, and is more cost effective, compared to co-mixing adipose derived stem cells with a tissue engineered construct. There is no need to spend the extra time and effort to isolate the stem cells from the adipose tissue. In addition, there is no risk of introducing the harmful, potent enzymes that are used to break down the connective tissue and isolate the stem cells, products that are still not approved for use by the FDA. [0024] It is to be understood that the present invention is not limited to the embodiment(s) described above and illustrated herein, but encompasses any and all variations falling within the scope of the appended claims.

Claims

What is claimed is:
1. A fill material for injection into a human patient, comprising: human fat harvested from a patient; and a gel suspension co-mixed with the fat.
2. The fill material of claim 1, wherein the gel suspension is hyaluronic acid.
3. The fill material of claim 1, wherein the gel suspension is poly-L-lactic acid.
4. The fill material of claim 1 , wherein the gel suspension is human-based collagen.
5. The fill material of claim 1, wherein the gel suspension is bovine-based collagen.
6. The fill material of claim 1, wherein the gel suspension is fibrin glue.
7. The fill material of claim 1, wherein the gel suspension is an alginate gel.
8. The fill material of claim 1, wherein the gel suspension is a monomer.
9. The fill material of claim 1, wherein the gel suspension is a polymer.
10. The fill material of claim 1, wherein the human fat and the gel suspension are co-mixed at a ratio of one to one.
PCT/US2007/024094 2006-11-16 2007-11-16 Co-mixed human fat and gel suspension implant material WO2008063569A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85987706P 2006-11-16 2006-11-16
US60/859,877 2006-11-16
US94092307A 2007-11-15 2007-11-15
US11/940,923 2007-11-15

Publications (1)

Publication Number Publication Date
WO2008063569A1 true WO2008063569A1 (en) 2008-05-29

Family

ID=39430019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/024094 WO2008063569A1 (en) 2006-11-16 2007-11-16 Co-mixed human fat and gel suspension implant material

Country Status (1)

Country Link
WO (1) WO2008063569A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012112757A3 (en) * 2011-02-17 2014-01-09 Allergan, Inc. Compositions and improved soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8900571B2 (en) 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8926963B2 (en) 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US9248384B2 (en) 2013-10-02 2016-02-02 Allergan, Inc. Fat processing system
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US9795711B2 (en) 2011-09-06 2017-10-24 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9867939B2 (en) 2013-03-12 2018-01-16 Allergan, Inc. Adipose tissue combinations, devices, and uses thereof
US10265477B2 (en) 2013-05-23 2019-04-23 Allergan, Inc. Mechanical syringe accessory
US10433928B2 (en) 2015-03-10 2019-10-08 Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company Multiple needle injector
US10463595B2 (en) 2008-09-02 2019-11-05 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US10596321B2 (en) 2016-04-08 2020-03-24 Allergan, Inc. Aspiration and injection device
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
US10792427B2 (en) 2014-05-13 2020-10-06 Allergan, Inc. High force injection devices
US10806821B2 (en) 2010-01-13 2020-10-20 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US10905797B2 (en) 2010-03-22 2021-02-02 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US10994049B2 (en) 2011-06-03 2021-05-04 Allergan Industrie, Sas Dermal filler compositions for fine line treatment
US11000626B2 (en) 2011-06-03 2021-05-11 Allergan Industrie, Sas Dermal filler compositions including antioxidants
US11083684B2 (en) 2011-06-03 2021-08-10 Allergan Industrie, Sas Dermal filler compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US20060093644A1 (en) * 2004-08-20 2006-05-04 Gerhard Quelle Methods of administering microparticles combined with autologous body components

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US20060093644A1 (en) * 2004-08-20 2006-05-04 Gerhard Quelle Methods of administering microparticles combined with autologous body components

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11154484B2 (en) 2008-09-02 2021-10-26 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US10463595B2 (en) 2008-09-02 2019-11-05 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US10806821B2 (en) 2010-01-13 2020-10-20 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US10905797B2 (en) 2010-03-22 2021-02-02 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US8900571B2 (en) 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8926963B2 (en) 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
WO2012112757A3 (en) * 2011-02-17 2014-01-09 Allergan, Inc. Compositions and improved soft tissue replacement methods
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US10994049B2 (en) 2011-06-03 2021-05-04 Allergan Industrie, Sas Dermal filler compositions for fine line treatment
US11000626B2 (en) 2011-06-03 2021-05-11 Allergan Industrie, Sas Dermal filler compositions including antioxidants
US10624988B2 (en) 2011-06-03 2020-04-21 Allergan Industrie, Sas Dermal filler compositions including antioxidants
US11083684B2 (en) 2011-06-03 2021-08-10 Allergan Industrie, Sas Dermal filler compositions
US9782517B2 (en) 2011-09-06 2017-10-10 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US11833269B2 (en) 2011-09-06 2023-12-05 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9821086B2 (en) 2011-09-06 2017-11-21 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9795711B2 (en) 2011-09-06 2017-10-24 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US11844878B2 (en) 2011-09-06 2023-12-19 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US9867939B2 (en) 2013-03-12 2018-01-16 Allergan, Inc. Adipose tissue combinations, devices, and uses thereof
US10265477B2 (en) 2013-05-23 2019-04-23 Allergan, Inc. Mechanical syringe accessory
US10369500B2 (en) 2013-10-02 2019-08-06 Allergan, Inc. Fat processing system
US9248384B2 (en) 2013-10-02 2016-02-02 Allergan, Inc. Fat processing system
US10792427B2 (en) 2014-05-13 2020-10-06 Allergan, Inc. High force injection devices
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
US10433928B2 (en) 2015-03-10 2019-10-08 Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company Multiple needle injector
US10596321B2 (en) 2016-04-08 2020-03-24 Allergan, Inc. Aspiration and injection device
US11890457B2 (en) 2016-04-08 2024-02-06 Allergan, Inc. Aspiration and injection device

Similar Documents

Publication Publication Date Title
WO2008063569A1 (en) Co-mixed human fat and gel suspension implant material
Annamalai et al. Injectable osteogenic microtissues containing mesenchymal stromal cells conformally fill and repair critical-size defects
Bai et al. Bioactive hydrogels for bone regeneration
Li et al. Collagen-based implants reinforced by chitin fibres in a goat shank bone defect model
JP4628756B2 (en) Tissue repair implant, manufacturing method thereof, and tissue repair method
Young et al. Injectable biomaterials for adipose tissue engineering
Lee et al. Enhanced regeneration of the ligament–bone interface using a poly (l-lactide–co-ε-caprolactone) scaffold with local delivery of cells/BMP-2 using a heparin-based hydrogel
US20160235889A1 (en) Silk/platelet composition and use thereof
Kutikov et al. Templated repair of long bone defects in rats with bioactive spiral-wrapped electrospun amphiphilic polymer/hydroxyapatite scaffolds
Zhao et al. Osteogenic media and rhBMP-2-induced differentiation of umbilical cord mesenchymal stem cells encapsulated in alginate microbeads and integrated in an injectable calcium phosphate-chitosan fibrous scaffold
KR101279812B1 (en) A manufacturing method of cartilage tissue repair composition
JP2014520844A (en) Chondrocyte therapeutic agent comprising collagen, hyaluronic acid derivative and mammalian umbilical cord-derived stem cells
Li et al. Biomimetic methacrylated gelatin hydrogel loaded with bone marrow mesenchymal stem cells for bone tissue regeneration
Ercan et al. Clinical applications of injectable biomaterials
Lin et al. A bilineage thermosensitive hydrogel system for stimulation of mesenchymal stem cell differentiation and enhancement of osteochondral regeneration
JP2021533882A (en) Methods for Producing Three-Dimensional Autologous Adipose Tissue Using Adipose Tissue Derived from Human Liposuctions Containing Pluripotent Stem Cells and Biocompatible Cellulose Nanofibrils
Theodoridis et al. In vivo cartilage regeneration with cell-seeded natural biomaterial scaffold implants: 15-year study
Kimura et al. In situ adipogenesis in fat tissue augmented by collagen scaffold with gelatin microspheres containing basic fibroblast growth factor
Lee et al. Breast reconstruction
US20230044236A1 (en) Medical Composition Comprising Adipose Tissue-Derived Extracellular Matrix And Method For Preparing Same
KR101582380B1 (en) Biomaterials for cell delivery and tissue regeneration for damaged tissue and method for preparing them
KR20100072430A (en) Method and device for injecting polymer fiber
Pourentezari et al. A Review of Tissue‐Engineered Cartilage Utilizing Fibrin and Its Composite
EP1987804A1 (en) Implantable system for an intervertebral disc and intervertebral disc implant
KR100956267B1 (en) A semi-floating composition for transplant comprising elastin as a stabilizing agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07862089

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07862089

Country of ref document: EP

Kind code of ref document: A1